相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Low concentrations of doxorubicin sensitizes human solid cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-receptor (R) 2-mediated apoptosis by inducing TRAIL-R2 expression
Xiu-Xian Wu et al.
CANCER SCIENCE (2007)
Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin
Larisa L. Belyanskaya et al.
MOLECULAR CANCER (2007)
Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers
Ruth Plummer et al.
CLINICAL CANCER RESEARCH (2007)
Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model
Liang Zhang et al.
CANCER LETTERS (2007)
Human agonistic antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 induces cytotoxicity and apoptosis in prostate cancer and bladder cancer cells
Osamu Shimada et al.
UROLOGY (2007)
Novel in vivo imaging shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies
Jing Gong et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death
GV Georgakis et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer
MM McCarthy et al.
CLINICAL CANCER RESEARCH (2005)
Expression of TRAIL and TRAIL receptors in normal and malignant tissues
RA Daniels et al.
CELL RESEARCH (2005)
Expression of tumour necrosis factor-related apoptosis-inducing ligand death receptors in sporadic and hereditary colorectal tumours: Potential targets for apoptosis induction
JJ Koornstra et al.
EUROPEAN JOURNAL OF CANCER (2005)
Death to the bad guys: Targeting cancer via Apo2L/TRAIL
S Bouralexis et al.
APOPTOSIS (2005)
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: Recommendations from the prostate-specific antigen working group
HI Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Apo2L/TRAIL and its death and decoy receptors
HN LeBlanc et al.
CELL DEATH AND DIFFERENTIATION (2003)
Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity
K Ichikawa et al.
NATURE MEDICINE (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
